major insurance changes are coming to glp 1 drugs Medicaid Coverage of and Spending on GLP-1s A new Medicare pilot is
Description
How many people take GLP-1 medications
Outcomes included changes in left ventricular ejection fraction (LVEF), end-diastolic volume (LVEDV), end-systolic volume (LVESV), global longitudinal strain (GLS), left ventricular mass, left atrial volume (LAV), and NT-proBNP levels
This is a year-over-year improvement of 30 percentage points, almost doubling after three years
The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.
Many individuals experience energy dips during GLP-1 therapy
You've heard the buzz about semaglutide and tirzepatide for weight loss, but let's clear up the myths
